The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma

BJU Int. 2009 Mar;103(6):740-6. doi: 10.1111/j.1464-410X.2008.08113.x. Epub 2008 Oct 24.

Abstract

Objective: To report the results of a programme aimed at determining the feasibility of autologous renal cell carcinoma (RCC) tissue collection and vaccine preparation within the setting of a UK National Health Service Cancer Centre.

Patients and methods: Patients undergoing nephrectomy for suspected renal tumours were identified from theatre lists between April 2005 and July 2007. Samples of tumour were freshly cut from nephrectomy specimens. If tissue collection failed the reason was recorded prospectively. Cell viability was assessed after sample sieving. Freeze-thaw lysates were prepared from viable tumour cells, and the immunogenicity tested by pulsing onto dendritic cells (DC).

Results: Of 84 patients, 83 had a histological diagnosis of RCC; samples were obtained from 29 of these 83 (35%). Reasons for failure in tissue collection included that the tumour was too small or haemorrhagic/necrotic, pre-surgical embolization, and difficulties with fresh tumour collection out of normal working hours. Viable tumour cells were obtained in 12 of the 29 samples (41%); no factor was able to predict the production of viable cells. Unmodified lysates did not activate DC.

Conclusion: An autologous RCC vaccination programme might fail to generate vaccines for a substantial proportion of eligible patients in the setting of a clinical cancer centre.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic
  • Adult
  • Aged
  • Aged, 80 and over
  • Cancer Vaccines*
  • Carcinoma, Renal Cell / prevention & control*
  • Dendritic Cells / transplantation
  • Enzyme-Linked Immunosorbent Assay
  • Epidemiologic Methods
  • Female
  • Flow Cytometry
  • Humans
  • Interleukin-10 / metabolism
  • Interleukin-12 / metabolism
  • Kidney Neoplasms / prevention & control*
  • Male
  • Middle Aged
  • Nephrectomy
  • Program Evaluation
  • Tissue Banks

Substances

  • Adjuvants, Immunologic
  • Cancer Vaccines
  • Interleukin-10
  • Interleukin-12